Conde-Sala JL, Garre-Olmo J, Vilalta-Franch J, Llinas-Regla J, Turro-Garriga O, Lozano-Gallego M, Hernandez-Ferrandiz M, Pericot-Nierga I, Lopez-Pousa S (2013) <br />[Cognitive decline in Alzheimer's disease. A follow three or more years of a sample of patients]<br /><i>Rev Neurol</i> <b>56</b>: 593<br /><br />Lopez-Pousa S, Arranz FJ (2013) <br />Characteristics of patients with Alzheimer's disease who switch to rivastigmine transdermal patches in routine clinical practice<br /><i>Patient Prefer Adherence</i> <b>7</b>: 47<br /><br />Lopez-Pousa S, Calvo-Perxas L, Lejarreta S, Cullell M, Melendez R, Hernandez E, Bisbe J, Perkal H, Manzano A, Roig AM, Turro-Garriga O, Vilalta-Franch J, Garre-Olmo J (2012) <br />Use of antidementia drugs in frontotemporal lobar degeneration<br /><i>Am J Alzheimers Dis Other Demen</i> <b>27</b>: 260<br /><br />Lopez-Pousa S, Turro-Garriga O, Calvo-Perxas L, Carmona O, Gich J, Alsina E, Marquez F, Vinas M, Turbau J, Vilalta-Franch J, Roig AM, Garre-Olmo J (2012) <br />Consumption of pharmaceuticals in primary non-Alzheimer's degenerative dementias : a cross-sectional study by the Registry of Dementias of Girona (ReDeGi)<br /><i>Drugs & Aging</i> <b>29</b>: 733<br /><br />Vilalta-Franch J, Lopez-Pousa S, Garre-Olmo J, Turon-Estrada A, Pericot-Nierga I (2008) <br />[Metabolic syndrome in Alzheimer's disease: clinical and developmental influences]<br /><i>Rev Neurol</i> <b>46</b>: 13<br /><br />Vilalta-Franch J, Lopez-Pousa S, Garre-Olmo J, Turon-Estrada A, Pericot-Nierga I (2008) <br />[Mortality rates in patients with Alzheimer's disease treated with atypical neuroleptic drugs]<br /><i>Rev Neurol</i> <b>46</b>: 129<br /><br />Lopez-Pousa S, Garre Olmo J, Vilalta Franch J, Turon Estrada A, Soler Cors O, Pericot Nierga I (2006) <br />[Mortality-associated factors in patients with Alzheimer's disease treated with galantamine.]<br /><i>Med Clin (Barc)</i> <b>127</b>: 206<br /><br />Lopez-Pousa S, Olmo JG, Franch JV, Estrada AT, Cors OS, Nierga IP, Gelada-Batlle E (2006) <br />Comparative analysis of mortality in patients with Alzheimer's disease treated with donepezil or galantamine<br /><i>Age Ageing</i> <b>35</b>: 365<br /><br />Lopez-Pousa S, Turon-Estrada A, Garre-Olmo J, Pericot-Nierga I, Lozano-Gallego M, Vilalta-Franch M, Hernandez-Ferrandiz M, Morante-Munoz V, Isern-Vila A, Gelada-Batlle E, Majo-Llopart J (2005) <br />Differential efficacy of treatment with acetylcholinesterase inhibitors in patients with mild and moderate Alzheimer's disease over a 6-month period<br /><i>Dementia & Geriatric Cognitive Disorders</i> <b>19</b>: 189<br /><br />Lopez-Pousa S, Lombardia Fernandez C (1999) <br />[Treatment of Alzheimer's disease: acetylcholinesterase inhibitors].<br /><i>Neurologia</i> <b>14</b>: 180<br /><br />Vilalta-Franch J, Lopez-Pousa S, Llinas-Regla J (1999) <br />[Treatment for non-cognitive symptoms in Alzheimer's disease]<br /><i>Rev Neurol</i> <b>29</b>: 819<br /><br />Lopez-Pousa S, Serra-Mestres J (1998) <br />[Medical treatment of Alzheimer's disease].<br /><i>Rev Neurol</i> <b>26</b>: 1054<br /><br />